Benzene and Acute Myeloid Leukemia: Evidence of Causation and Risk

From General Health Surveillance to Occupational Risk Assessment

The Immunodeficiency Foundation’s archival mission has long centered on the broad dissemination of general health and science information, with a particular emphasis on immunological function and environmental influences on human well-being. Its historical collections have documented how various external factors—from nutritional deficiencies to infectious agents—can disrupt normal physiological processes, providing a foundational understanding of disease risk that spans multiple domains of public health. This legacy of contextualizing health threats within their environmental and occupational settings now serves as a natural bridge to more specialized areas of inquiry. Among the most extensively studied environmental exposures in occupational health is benzene, a widely used industrial solvent whose association with hematological outcomes has been a focus of epidemiological research for decades.

Bridging to Benzene and Acute Myeloid Leukemia

The transition from general health surveillance to targeted occupational risk assessment is particularly evident in the evolution of studies examining benzene’s relationship with acute myeloid leukemia (AML). While the Immunodeficiency Foundation’s archives have historically addressed broad population-level health patterns, the shift toward occupational exposure concern requires a more focused lens—one that examines specific workplace environments where benzene concentrations may be elevated and where sustained exposure over time becomes a critical variable in understanding disease causation. This pivot from general context to occupational specificity represents a logical extension of the foundation’s archival principles.

Clinical Presentation and Diagnosis of Acute Myeloid Leukemia

AML is a hematologic malignancy characterized by the rapid proliferation of abnormal myeloid precursor cells in the bone marrow and peripheral blood. Clinical presentation typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, as well as signs of extramedullary involvement. Diagnosis is confirmed through bone marrow aspiration and biopsy, demonstrating at least 20% blasts in the marrow or blood, along with cytogenetic and molecular profiling. The disease can arise de novo or secondary to prior chemotherapy, radiation, or exposure to myelotoxic agents like benzene.

Benzene Pharmacology and Reported Adverse Effects

Benzene is a volatile organic compound widely used as an industrial solvent and a component of gasoline. Chronic exposure, particularly through inhalation in occupational settings, is known to cause hematotoxicity. Benzene is metabolized in the liver to reactive intermediates, including benzene oxide, phenol, and hydroquinone, which can accumulate in the bone marrow. These metabolites induce oxidative stress, inflammation, and direct DNA damage, leading to bone marrow suppression, aplastic anemia, myelodysplastic syndromes (MDS), and AML. The adverse effects are dose-dependent, with increased risk observed at occupational exposure levels of 10 parts per million (ppm) or more (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Mechanistic Pathways Linking Benzene to Acute Myeloid Leukemia

The mode of action (MOA) for benzene-induced AML involves multiple key events. Initial hematotoxicity and genetic toxicity in peripheral blood are early indicators of bone marrow damage (https://pubmed.ncbi.nlm.nih.gov/33429013/). Mechanistically, benzene exerts its carcinogenic effects through several pathways: genotoxicity (direct DNA damage and chromosomal aberrations), induction of oxidative stress and inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). Additionally, epigenetic alterations, such as changes in gene expression, are increasingly recognized as contributing factors that may explain phenomena not fully accounted for by genetic mutations alone (https://pubmed.ncbi.nlm.nih.gov/34069279/). These early events, if not prevented, can progress to MDS and ultimately AML, leading to morbidity and mortality.

Epidemiological Evidence of Causation

Multiple studies have established a causal relationship between benzene exposure and AML. Occupational exposure to benzene at levels of 10 ppm or more has been associated with increased AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). A meta-analysis of 25 studies found that benzene exposure was associated with an elevated risk of AML in children, with an odds ratio (OR) of 1.22 (95% confidence interval [CI]: 1.02–1.46) per 1 μg/m³ increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). In a large Swiss national cohort, occupational benzene exposure was linked to elevated mortality risks for AML, as well as for diffuse large B-cell lymphoma and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). These findings reinforce the consistency of the association across different populations and exposure settings.

Adequacy of Warnings and Causation Considerations

Given the well-documented risks, adequate warnings regarding benzene exposure are critical for prevention. However, the adequacy of such warnings in occupational and consumer contexts remains a concern. For affected patients, causation considerations include the intensity and duration of exposure, latency period, and the presence of other risk factors. The timeline between benzene exposure and development of AML can vary, but early hematotoxic effects may be observed within months to years, while AML typically manifests after a longer latency, often decades. Prevention of early key events, such as hematotoxicity and genetic damage, is essential to reduce the risk of progression to AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Conclusion

The evidence strongly supports a causal link between benzene exposure and AML, mediated through genotoxic, oxidative, inflammatory, and epigenetic mechanisms. Epidemiological studies consistently demonstrate elevated risks in both occupational and environmental settings. Adequate warnings and exposure monitoring are necessary to protect at-risk populations, and early detection of hematologic abnormalities may help mitigate the progression to AML.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the evidence linking benzene to acute myeloid leukemia?

Multiple epidemiological studies have established a causal relationship between benzene exposure and AML. Occupational exposure at levels of 10 ppm or more increases AML risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). A meta-analysis of 25 studies found an elevated risk in children (OR 1.22 per 1 μg/m³) (https://pubmed.ncbi.nlm.nih.gov/41485753/). A Swiss national cohort linked occupational benzene exposure to increased AML mortality (https://pubmed.ncbi.nlm.nih.gov/38727681/).

How does benzene cause acute myeloid leukemia?

Benzene is metabolized to reactive intermediates that cause genotoxicity, oxidative stress, inflammation, and immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). These mechanisms lead to bone marrow damage, myelodysplastic syndromes, and ultimately AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.